Omnicell (NASDAQ:OMCL) Issues Earnings Results

Omnicell (NASDAQ:OMCL) released its quarterly earnings data on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16, Briefing.com reports. The business had revenue of $307.85 million for the quarter, compared to the consensus estimate of $304.44 million. Omnicell had a return on equity of 5.69% and a net margin of 3.59%. The company’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Here are the key takeaways from Omnicell’s conference call:

• Third-quarter results exceeded guidance, with revenue of $308 million and non-GAAP EBITDA of $45 million, supported by favorable product mix, gross margins, disciplined spending, and cost efficiencies.
• Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and EPS guidance to $2.48–$2.56, while narrowing revenue and ARR ranges because of improved visibility.
• The company said the Titan XT and OmniSphere pipeline grew modestly and became more mature, with Titan XT shipments beginning shortly and OmniSphere general availability still targeted for the first half of 2027. Management views OmniSphere subscriptions as a potentially high-margin, incremental revenue stream over time.
• Product bookings remain heavily back-end weighted, and management cited the timing of medium and large health-system decisions, competitive deal outcomes, and lengthy implementation cycles as sources of quarter-to-quarter variability.
• Second-half memory and component costs are expected to reduce margins by roughly $6 million, with about half incurred in the third quarter and the remainder expected in the fourth quarter; policy changes surrounding the 340B program are also expected to have a modest impact on 2026 ARR.

Omnicell Trading Down 0.6%

Shares of Omnicell stock traded down $0.23 on Friday, reaching $36.65. The company had a trading volume of 785,543 shares, compared to its average volume of 511,906. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of 38.18, a P/E/G ratio of 0.93 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.65 and a quick ratio of 1.43. The firm’s 50-day moving average price is $34.60 and its two-hundred day moving average price is $39.11. Omnicell has a 1 year low of $31.75 and a 1 year high of $55.00.

Analyst Ratings Changes

Several equities research analysts recently weighed in on OMCL shares. Piper Sandler restated an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Wells Fargo & Company reduced their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell News Summary

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported third-quarter adjusted earnings of $0.58 per share, well above the $0.42 analyst consensus and up from $0.51 a year earlier. Revenue of $307.9 million also exceeded the $304.4 million estimate, marking the company’s sixth consecutive earnings beat. Omnicell Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Improved service performance and margins were a key earnings driver. Service revenue increased to $134.8 million from $133.1 million year over year, while GAAP net income nearly doubled to $11.0 million, or $0.24 per diluted share. Omnicell Q3 2026: Service Margins Power a Sixth Straight Earnings Beat
• Neutral Sentiment: Management updated full-year 2026 guidance to $1.225 billion-$1.231 billion in revenue, $187 million-$193 million in adjusted EBITDA, and $2.48-$2.56 in adjusted earnings per share. The outlook suggests continued profitability improvement, but leaves limited room for upside if demand remains muted. Omnicell Provides Fourth-Quarter and Full-Year Guidance
• Negative Sentiment: Quarterly revenue declined about 1% year over year to $307.9 million, with product revenue falling to $173.1 million from $177.5 million. Fourth-quarter revenue guidance of $295 million-$301 million appears weaker than investor expectations, overshadowing the earnings beat and likely explaining the stock’s decline. Omnicell Exceeds Q3 Expectations but Quarterly Revenue Guidance Misses
• Negative Sentiment: Reported insider activity was entirely selling over the past six months, including sales by CEO Randall Lipps and President and COO Nnamdi Njoku. While not directly tied to the quarter, the activity may add to investor caution. Omnicell Reports Third-Quarter Revenue and GAAP Net Income

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.